Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference — Oct 2nd, 2024

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in n...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% — Oct 15th, 2024

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash, on a fully diluted basis. Shares of LBPH surged 5...